Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
-
Noosa News11 hours ago‘Just want to know he’s safe’: Family’s German Shepherd asleep in back of stolen ute
-
Noosa News20 hours agoMan allegedly exposed himself to teen girls in Newstead, Springfield; Dingo snatches shark on K’gari; BBC boss and news chief quit over Trump video outrage
-
Noosa News15 hours agoQueensland Cross-Border Commissioner and former police union boss Ian Leavers found dead at Brisbane home
-
General21 hours agoAFL gives teams finishing 10th chance to win premiership through wildcard round in finals